GI Esophageal / Gastric

Localized

Metastatic

HER 2+

1st Line

2nd Line

IRB #15349
Keynote-181
A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

IRB #15706
EMR100070-007: Phase III open-label, of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

HER 2-

1st Line

2nd Line

IRB #15349
Keynote-181
A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

No Trials Currently Available

IRB #12071
Trial to be available soon

www.ohsu.edu/cancer

10/4/2016